Molecular Glues Were Discovered by Accident. Not Anymore.
Molecular glues are biotech's hottest modality and its hardest to design rationally. Ternary thinks AI can change that.
Jeff Martin
What If B-Cell Depletion Didn’t Need T Cells at All?
Commit Biologics raises €21.5M to weaponize the complement system against B cells — no cytokine storm required.
Antiverse
Antiverse is using generative AI to crack the 220 undrugged GPCRs that conventional discovery can't touch.
NEOK Bio
NEOK is building on of the most ambitious bispecific ADC pipeline to hit the U.S. clinic.
The Splice Between Gene Editing and Gene Therapy
Tacit Therapeutics launches with $19M to build RNA splicing therapies that fix mutations without touching DNA.
220 Targets. Zero Antibodies. One AI Platform.
One-third of all FDA-approved drugs target GPCRs, but almost no antibodies do. Antiverse's AI platform is changing that — and the CF Foundation just signed on.
CRISPR Just Became an Antibiotic. Sort Of.
SNIPR Biome publishes first clinical proof that CRISPR-engineered phages can selectively kill bacteria in the human gut.